Entero Therapeutics, Inc.

NasdaqCM:ENTO Voorraadrapport

Marktkapitalisatie: US$2.2m

Entero Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Entero Therapeutics is forecast to grow earnings and revenue by 5.9% and 95.3% per annum respectively while EPS is expected to grow by 46.2% per annum.

Belangrijke informatie

5.9%

Groei van de winst

46.2%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei95.3%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt27 Sep 2024

Recente toekomstige groei-updates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

Jun 07

AzurRx BioPharma: An Assessment

May 02

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

Jan 31

Winst- en omzetgroeiprognoses

NasdaqCM:ENTO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026N/A-42N/AN/A1
12/31/2025N/A-32N/AN/A1
12/31/2024N/A-11N/AN/A1
6/30/2024N/A-10-14-14N/A
3/31/2024N/A-6-14-13N/A
12/31/2023N/A-16-13-12N/A
9/30/2023N/A-16-15-15N/A
6/30/2023N/A-8-15-15N/A
3/31/2023N/A-9-17-17N/A
12/31/2022N/A-15-22-22N/A
9/30/2022N/A-22-33-23N/A
6/30/2022N/A-57-44-34N/A
3/31/2022N/A-65-45-35N/A
12/31/2021N/A-85-43-32N/A
9/30/2021N/A-92-32-32N/A
6/30/2021N/A-74-19-19N/A
3/31/2021N/A-66-15-15N/A
12/31/2020N/A-42-11-11N/A
9/30/2020N/A-25-9-9N/A
6/30/2020N/A-15-10-10N/A
3/31/2020N/A-16-13-13N/A
12/31/2019N/A-15-14-14N/A
9/30/2019N/A-18-14-14N/A
6/30/2019N/A-16-13-13N/A
3/31/2019N/A-15-12-11N/A
12/31/2018N/A-14-11-11N/A
9/30/2018N/A-12-10-10N/A
6/30/2018N/A-13-9-9N/A
3/31/2018N/A-12N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-14N/A-7N/A
6/30/2017N/A-14N/A-7N/A
3/31/2017N/A-15N/A-5N/A
12/31/2016N/A-15N/A-5N/A
9/30/2016N/A-10N/A-3N/A
6/30/2016N/A-8N/A-4N/A
3/31/2016N/A-7N/A-4N/A
12/31/2015N/A-6N/A-4N/A
9/30/2015N/A-6N/A-4N/A
6/30/2015N/A-5N/A-3N/A
3/31/2015N/A-3N/A-2N/A
12/31/2014N/A-2N/A-1N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: ENTO is forecast to remain unprofitable over the next 3 years.

Winst versus markt: ENTO is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: ENTO is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: ENTO is forecast to have no revenue next year.

Hoge groei-inkomsten: ENTO is forecast to have no revenue next year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if ENTO's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven